相似文献
1
ICSBP-mediated immune protection against BCR-ABL-induced leukemia requires the CCL6 and CCL9 chemokines.
Blood. 2009 Apr 16;113(16):3813-20. doi: 10.1182/blood-2008-07-167189. Epub 2009 Jan 26.
2
Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder.
Mol Cell Biol. 2000 Feb;20(4):1149-61. doi: 10.1128/MCB.20.4.1149-1161.2000.
3
Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias.
Blood. 1998 Jan 1;91(1):22-9.
4
Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2.
Blood. 2004 May 1;103(9):3480-9. doi: 10.1182/blood-2003-08-2970. Epub 2003 Dec 4.
5
Bcr-abl regulates Stat5 through Shp2, the interferon consensus sequence binding protein (Icsbp/Irf8), growth arrest specific 2 (Gas2) and calpain.
Oncotarget. 2016 Nov 22;7(47):77635-77650. doi: 10.18632/oncotarget.12749.
6
ICSBP/IRF-8 inhibits mitogenic activity of p210 Bcr/Abl in differentiating myeloid progenitor cells.
Blood. 2003 Dec 15;102(13):4547-54. doi: 10.1182/blood-2003-01-0291. Epub 2003 Aug 21.
7
Expression of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukemia.
Blood. 2001 Jun 1;97(11):3491-7. doi: 10.1182/blood.v97.11.3491.
8
Retroviral integration site analysis identifies ICSBP as a collaborating tumor suppressor gene in NUP98-TOP1-induced leukemia.
Exp Hematol. 2006 Sep;34(9):1192-201. doi: 10.1016/j.exphem.2006.04.020.
9
Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-alpha.
Blood. 2001 Jun 1;97(11):3648-50. doi: 10.1182/blood.v97.11.3648.
10
Interferon consensus sequence binding protein (ICSBP) decreases beta-catenin activity in myeloid cells by repressing GAS2 transcription.
Mol Cell Biol. 2010 Oct;30(19):4575-94. doi: 10.1128/MCB.01595-09. Epub 2010 Aug 2.
引用本文的文献
1
Targeting serine/glycine metabolism improves radiotherapy response in non-small cell lung cancer.
Br J Cancer. 2024 Mar;130(4):568-584. doi: 10.1038/s41416-023-02553-y. Epub 2023 Dec 30.
2
Chemokine CCL6 Plays Key Role in the Inhibitory Effect of Vitamin A on Norovirus Infection.
J Microbiol. 2023 May;61(5):579-587. doi: 10.1007/s12275-023-00047-3. Epub 2023 May 26.
3
Mouse CCL9 Chemokine Acts as Tumor Suppressor in a Murine Model of Colon Cancer.
Curr Issues Mol Biol. 2023 Apr 15;45(4):3446-3461. doi: 10.3390/cimb45040226.
4
Sublytic C5b-9 Induces CCL3/4 Production and Macrophage Accumulation in Thy-1N Rats via PKC-α/p65/IRF-8 Axis.
Int J Biol Sci. 2022 May 1;18(8):3178-3193. doi: 10.7150/ijbs.69652. eCollection 2022.
5
TRIB2 regulates the expression of miR‑33a‑5p through the ERK/c‑Fos pathway to affect the imatinib resistance of chronic myeloid leukemia cells.
Int J Oncol. 2022 May;60(5). doi: 10.3892/ijo.2022.5339. Epub 2022 Mar 18.
6
CCL23 in Balancing the Act of Endoplasmic Reticulum Stress and Antitumor Immunity in Hepatocellular Carcinoma.
Front Oncol. 2021 Oct 4;11:727583. doi: 10.3389/fonc.2021.727583. eCollection 2021.
7
Identification of a Hematopoietic Cell Population Emerging From Mouse Bone Marrow With Proliferative Potential and Immunomodulatory Capacity.
Front Immunol. 2021 Aug 3;12:698070. doi: 10.3389/fimmu.2021.698070. eCollection 2021.
8
IRF8 Is an AML-Specific Susceptibility Factor That Regulates Signaling Pathways and Proliferation of AML Cells.
Cancers (Basel). 2021 Feb 12;13(4):764. doi: 10.3390/cancers13040764.
9
Antitumor T-cell Immunity Contributes to Pancreatic Cancer Immune Resistance.
Cancer Immunol Res. 2021 Apr;9(4):386-400. doi: 10.1158/2326-6066.CIR-20-0272. Epub 2021 Jan 28.
10
Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia.
Leukemia. 2020 Aug;34(8):2087-2101. doi: 10.1038/s41375-020-0866-1. Epub 2020 May 21.
本文引用的文献
1
The chemokine CCL6 promotes innate immunity via immune cell activation and recruitment.
J Immunol. 2007 Oct 15;179(8):5474-82. doi: 10.4049/jimmunol.179.8.5474.
2
The role of interferon-alpha in the treatment of chronic myeloid leukemia.
Cytokine Growth Factor Rev. 2007 Oct-Dec;18(5-6):459-71. doi: 10.1016/j.cytogfr.2007.06.015. Epub 2007 Aug 20.
3
Expression of CCL9/MIP-1gamma is repressed by BCR/ABL and its restoration suppresses in vivo leukemogenesis of 32D-BCR/ABL cells.
Oncogene. 2007 May 24;26(24):3482-91. doi: 10.1038/sj.onc.1210146. Epub 2006 Dec 11.
4
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen.
Cell. 2006 Mar 24;124(6):1283-98. doi: 10.1016/j.cell.2006.01.040.
5
The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance.
Leukemia. 2006 Jan;20(1):61-7. doi: 10.1038/sj.leu.2403998.
6
FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism.
Mol Cell Biol. 2004 Nov;24(22):10058-71. doi: 10.1128/MCB.24.22.10058-10071.2004.
7
Adoptive immunotherapy of BCR-ABL-induced chronic myeloid leukemia-like myeloproliferative disease in a murine model.
Blood. 2004 Dec 15;104(13):4236-44. doi: 10.1182/blood-2004-06-2229. Epub 2004 Aug 12.
8
The interferon regulatory factor ICSBP/IRF-8 in combination with PU.1 up-regulates expression of tumor suppressor p15(Ink4b) in murine myeloid cells.
Blood. 2004 Jun 1;103(11):4142-9. doi: 10.1182/blood-2003-01-0285. Epub 2004 Feb 19.
9
Immunological effects of interferon-alpha on chronic myelogenous leukemia.
Leuk Lymphoma. 2003 Dec;44(12):2061-7. doi: 10.1080/1042819031000110973.
10
Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2.
Blood. 2004 May 1;103(9):3480-9. doi: 10.1182/blood-2003-08-2970. Epub 2003 Dec 4.
Zotero 插件